Verona Pharma (VRNA) to Release Earnings on Monday

Verona Pharma (NASDAQ:VRNA) is scheduled to release its earnings data before the market opens on Monday, November 4th. Analysts expect Verona Pharma to post earnings of ($0.44) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same period last year, the company earned ($0.11) earnings per share. On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Verona Pharma Stock Up 3.1 %

Shares of NASDAQ:VRNA opened at $34.98 on Friday. The firm has a market cap of $2.80 billion, a P/E ratio of -22.71 and a beta of 0.44. The company has a quick ratio of 8.61, a current ratio of 8.61 and a debt-to-equity ratio of 0.72. Verona Pharma has a 12-month low of $11.39 and a 12-month high of $35.62. The business has a fifty day simple moving average of $30.61 and a 200 day simple moving average of $22.09.

Insider Transactions at Verona Pharma

In other news, CEO David Zaccardelli sold 110,456 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $4.38, for a total value of $483,797.28. Following the transaction, the chief executive officer now owns 14,894,464 shares in the company, valued at $65,237,752.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO David Zaccardelli sold 110,456 shares of Verona Pharma stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $4.38, for a total value of $483,797.28. Following the sale, the chief executive officer now owns 14,894,464 shares of the company’s stock, valued at approximately $65,237,752.32. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mark W. Hahn sold 249,728 shares of Verona Pharma stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,093,808.64. Following the completion of the sale, the chief financial officer now directly owns 14,089,960 shares in the company, valued at $61,714,024.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 868,840 shares of company stock worth $3,805,519 in the last 90 days. Insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Verona Pharma in a research report on Thursday, October 3rd. They issued an “overweight” rating and a $50.00 price objective for the company. Truist Financial lifted their price objective on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Verona Pharma in a research note on Tuesday, October 1st. Finally, Canaccord Genuity Group raised their target price on Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $39.33.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.